back to US directory
us clinical guidance

Kidney-stone metabolic evaluation and recurrence prevention

US stone analysis, risk assessment, urine evaluation, diet, phenotype-directed prevention and longitudinal monitoring after nephrolithiasis.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults after a kidney or ureteral stone, with emphasis on recurrent, bilateral, multiple or otherwise high-risk stone formation. This page complements the acute-stone page and uses the still-listed 2014 AUA medical guideline, whose validity was confirmed in 2019 while a replacement was in development at the 2026 source check.
sources for this section:AUA medical stones

The Bottom Line

  • Perform a screening evaluation for every newly diagnosed stone former, including medical and diet history, urinalysis and appropriate serum studies, and obtain stone composition when material is available.
  • Offer a fuller metabolic evaluation to recurrent or high-risk stone formers and interested first-time patients, using one or more properly collected 24-hour urine samples and phenotype-directed blood testing.
  • Encourage fluid intake sufficient to maintain a high daily urine volume, while adapting the plan for heart failure, advanced CKD, hyponatremia risk or another fluid restriction.
  • Avoid indiscriminate calcium restriction; use normal dietary calcium with meal timing, moderate sodium and animal-protein excess, and tailor oxalate, purine or alkali advice to stone and urine findings.
  • Use thiazide-type therapy, citrate, allopurinol or another preventive medicine only for the relevant metabolic phenotype, with contraindication, interaction and laboratory monitoring.
sources for this section:AUA medical stones

Practical clinical workflow

1
Review number and timing of stones, procedures, infections, bowel disease or surgery, gout, osteoporosis, family history, occupation, diet, supplements and medicines that alter stone risk.
2
Analyze a retrieved stone and obtain serum and urine studies; consider parathyroid hormone when hyperparathyroidism is suspected and evaluate infection or genetic disease when the phenotype suggests it.
3
For a high-risk or recurrent patient, collect a complete 24-hour urine under usual conditions and interpret volume, calcium, oxalate, citrate, uric acid, sodium, pH and other reported measures together.
4
Agree on a small number of specific diet or medication targets, address barriers and repeat laboratory or urine assessment after an interval that can demonstrate adherence and biochemical response.
5
Continue periodic imaging or clinical monitoring matched to stone activity, radiation exposure and anatomy, and revise treatment when stones recur despite apparent biochemical improvement.
sources for this section:AUA medical stones

Safety boundaries and escalation

  • Recurrent infection stones, staghorn burden, declining kidney function, childhood onset, nephrocalcinosis, a solitary kidney or suspected monogenic disease warrants specialist evaluation.
  • Potassium citrate can cause hyperkalemia and thiazide-type drugs can alter sodium, potassium, glucose, uric acid and blood pressure; monitor according to kidney function and comorbidity.
  • Over-the-counter vitamin C, calcium, vitamin D, protein, alkali and herbal products can change stone risk or interact with disease; document dose and indication rather than advising blanket discontinuation.
  • A prevention plan does not manage fever, obstruction or acute renal colic; use the acute-stone safety pathway for new symptomatic episodes.
sources for this section:AUA medical stones

Localization

The cited AUA medical guideline is older, its validity was confirmed in 2019 and a replacement was in development at the source check; recheck its status at every scheduled review. Use US laboratory units, current FDA labels and local dietitian and urology access.
sources for this section:AUA medical stones

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American Urological AssociationMedical Management of Kidney Stones: AUA GuidelinePMID 24857648 路 2014 guideline; validity confirmed 2019; replacement listed as in development on 2026-08-20 路 published 2014-08-01 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.